Stocks Health care ERNA
NASDAQ · Health careErnexa Therapeutics Inc. (ERNA)
It posted a net loss of $12.3M. In fiscal 2025 capital spending exceeded operating cash flow by $7.1M. At June 30, 2026 it held $5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Ernexa Therapeutics Inc. does
Ernexa Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ERNA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$14.1M | -$2.24 | -$7.1M |
| 2024 | $582K | -$44.5M | -$48.96 | -$16.2M |
| 2023 | $68K | -$21.7M | -$61.28 | -$20.4M |
| 2022 | $0 | -$24.6M | -$121.05 | -$21.3M |
| 2021 | n/a | -$122.5M | -$850.19 | -$23.6M |
| 2020 | $5.8M | -$7.3M | -$123.17 | -$8.1M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Ernexa Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026
- September 16, 2026
- August 6, 2026
- July 2, 2026
- July 2, 2026
- June 26, 2026
- May 20, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Ernexa Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns ERNA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Charles Cherington13D, may seek influence | 34.7% | February 17, 2026 |
| Freebird Partners LP13G, passive with 2 related filers | 9.9% | May 15, 2026 |
| Shameek Konar13G, passive with 2 related filers | 9.7% | May 13, 2026 |
| Bleichroeder LP13G, passive with 2 related filers | 6.86% | May 14, 2026 |
| John D. Halpern13G, passive with 1 related filers | 5.6% | May 15, 2026 |
Largest institutional holders
Insiders
Questions about ERNA
What does Ernexa Therapeutics Inc. do?
Ernexa Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ERNA.
Is Ernexa Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $12.3M.
When did Ernexa Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new insider holdings from September 22, 2026.
Similar companies
Compare ERNA with
Follow ERNA
Get an email when Ernexa Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ERNA: get an email when it filesWhere the numbers come from
Financial figures are the values Ernexa Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.